Clinical Trial Update: A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating MK0812 for disease activity in Relapsing-Remitting Multiple Sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• MK0812

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED